BioGenes - antibody development with new technology platform
With the new platform BioGenes extends and improves its service offer especially for those customers only having a very small amount of antigen and little time for the project also. In contradiction to competitors stable clones (IgG) will be available within 3-4 months. The delivery of all positive stable clones to their customers has been a long-time company standard just like the fact that all project results as well as clones are of course their customer's property. The company now focuses on the further perfection of the technology. In consequence they will be in the position to provide their customers once more with enhanced first-class services.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.